黑料不打烊

Global Single-Use Bioprocessing Market Trends and Insights

Cost & CAPEX Avoidance vs. Stainless-Steel Plants

Replacing clean-in-place and steam-in-place hardware with disposable assemblies compresses green-field project timelines by up to two years and cuts capital budgets nearly in half. Peer-reviewed modeling of a 2,000 L monoclonal antibody campaign showed breakeven at only 12 batches a year, a level typical for multi-product CDMO facilities. Lonza reported that 70% of mammalian capacity added since 2023 employs single-use lines, citing quicker client onboarding^{[1]Lonza Group, “Annual Report 2024,” Lonza.com}. Updated FDA guidance allows stainless vessels to be swapped with validated disposables without triggering new comparability studies, further tilting the economic balance. These factors collectively underpin the structural shift captured in the single-use bioprocessing market.

CDMO and CMO Capacity Expansion

Global expansion of contract development and manufacturing capacity reflects a structural shift toward more agile and scalable biomanufacturing ecosystems. As biologics pipelines grow in complexity and diversification, manufacturers are increasingly prioritizing infrastructure that enables rapid deployment, multi-product flexibility, and reduced time-to-market. This evolution is particularly pronounced in advanced therapy segments such as cell and gene therapy, where batch sizes are smaller and sterility requirements are stringent. Fujifilm invested over USD 3.2 billion in its Holly Springs facility in North Carolina, USA, in April 2024, establishing it as one of the largest biologics CDMO sites globally. Additionally, the company allocated USD 1.6 billion to expand cell-culture capacity in Denmark. Both facilities are designed for large-scale biologics manufacturing, incorporating flexible designs with single-use systems for cell culture. These investments reflect the industry's shift toward modular biomanufacturing infrastructure, with single-use technologies driving market growth.

Rapid Scale-up Needs for mRNA Vaccines & Personalized Therapies

BARDA’s USD 1.2 billion program contracted modular suites capable of pivoting from pandemic vaccines to commercial products within six weeks. BioNTech is retrofitting its Marburg site with single-use fermentors for individualized cancer vaccines, a conversion financially unrealistic for stainless assets. Every FDA-approved autologous cell therapy facility now operates closed disposable paths to avoid patient cross-contamination. A recent CAR-T case study documented batch-turnaround cuts of one-third after eliminating cleaning validation steps. These speed demands reinforce growth in the single-use bioprocessing market.

Circular-Economy Mandates Favoring Polymer Recovery

The EU’s revised Single-Use Plastics Directive requires take-back schemes for polyethylene and polypropylene films over 10 kg per unit, directly impacting bioreactor bags. Sartorius and Veolia launched a Lyon pilot diverting 120 tons of film waste annually from incineration through mechanical recycling. Enzymatic depolymerization research shows promise but must contend with gamma-irradiation chain scission. ISPE quantified 0.8 tons of plastic per 2,000 L batch, a metric now embedded in many European tenders. Procurement teams increasingly weigh circularity alongside performance, shaping supplier roadmaps in the single-use bioprocessing market.

Leachables & Extractables Compliance Risk

FDA’s ANDA guidance now mandates extractables and leachables studies for every disposable component contacting drug substance, adding six to nine months and roughly USD 200,000 per product. ICH Q3E sets a 1.5 ?g/day genotoxic threshold that some plasticizers can surpass, forcing tighter gamma-irradiation controls. MilliporeSigma recalled 800 tubing sets after phthalate levels hit 4.2 ppm. USP chapters <665> and <1665> now require mass-spectrometry characterization above 0.1 ppm, a hurdle for small suppliers. Compliance costs temper near-term momentum in the single-use bioprocessing market.

Plastic-Waste Disposal & ESG Regulations

The EU directive imposes 30% recycling targets by 2028, compelling suppliers to finance take-back logistics. A sustainability review pegged plastic intensity at 0.8 t per 2,000 L antibody batch, with incineration still dominant in North America and APAC. Sartorius diverted 18% of returned disposables via French and German pilots but cited gamma-irradiation degradation as a technical hurdle. Investor coalitions managing USD 4 trillion demanded plastic-waste disclosures from the top 10 suppliers in early 2025. These ESG headwinds shave growth from the single-use bioprocessing market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Sensors Drive Margin Expansion

Single-use bioreactors dominated 2025 revenue, yet inline sensors are the fastest-growing product class. FlowVPE spectroscopy alone generated USD 42 million in its launch year, underscoring how analytics attach high margins to consumable sales^{[2]Repligen Corporation, “Investor Presentation 2025,” Repligen.com}. Filtration cassettes and media bags underpin buffer prep, while proprietary tubing geometries lock in recurring demand. Mixers benefit from continuous-manufacturing trends, with magnetic designs shortening media-prep cycles from eight hours to 90 minutes. The single-use bioprocessing market size for sensors is projected to expand briskly as AI-centric control schemes spread.

The competitive battleground pivots on ecosystem lock-in. Sartorius and Cytiva secure share through connector and bag exclusivity, discouraging third-party component substitution. Chromatography formats trail because reusable columns still underpin high-volume antibody workflows, yet membrane adsorbers are gaining as titers rise. Supplier R&D now funnels toward integrating disposable sensors, ensuring that data-rich operation remains inseparable from the broader single-use bioprocessing market.

By Workflow Stage: Downstream Gains Momentum

Upstream assets, especially bioreactors, accounted for a 52.53% single-use bioprocessing market share in 2025, reflecting long-standing maturity. Downstream units, however, post the quickest gains as continuous filtration and single-use TFF systems displace steel Protein A columns at high titers. A 0.5 m? disposable TFF cassette introduced in 2025 processes 500 L in a single pass, removing a 12-hour cleaning step. The single-use bioprocessing market size for downstream modules is projected to climb alongside hybrid continuous lines.

Continuous chromatography pilot data show 95% step yields with membrane adsorbers, cutting validation times and water consumption. Regulatory clarity from ICH Q13 accelerates adoption by defining control-strategy expectations. Fill-finish operations also lean on disposable tubing and pump heads that reduce product changeovers from eight hours to two. Collectively these shifts rebalance value from upstream to downstream within the single-use bioprocessing market.

By Application: Conventional Biopharma Leads, Regenerative Medicine Accelerates

Conventional biopharmaceuticals accounted for the majority of the single-use bioprocessing market revenue in 2025, supported by the continued production of monoclonal antibodies (mAbs), recombinant proteins, vaccines, and biosimilars. Biopharmaceutical manufacturers increasingly utilize single-use bioreactors, filtration systems, and mixing technologies to reduce capital expenditure, minimize contamination risks, and accelerate production timelines. The flexibility offered by disposable platforms is particularly valuable for multiproduct facilities, where rapid changeovers and reduced cleaning requirements improve operational efficiency and manufacturing throughput.

Regenerative medicine (advanced therapies) represents the fastest-growing application segment, driven by the expansion of cell therapies, gene therapies, and tissue-engineered products. These therapies are typically manufactured in small batches with highly specialized processes, making single-use systems an ideal solution due to their scalability, closed-system operation, and lower cross-contamination risk. The increasing number of clinical trials and commercial approvals for autologous and allogeneic therapies is accelerating demand for disposable bioprocessing technologies across upstream, downstream, and fill-finish operations.

By Scale: Commercial Dominates, Clinical Accelerates

Commercial-scale programs held two-thirds of 2025 revenue, widening as biosimilar launches crest. Disposable bioreactors now span 50 L to 5,000 L, letting firms use one platform from Phase I to launch. Cytiva said 40% of 2024 XDR sales were to customers planning dual clinical-commercial use, compressing tech-transfer timelines. A 2,000 L campaign reaches cost parity versus stainless steel at roughly 12 batches a year, a threshold most commercial antibodies exceed.

Retrofit activity is meaningful: 30% of Sartorius STR units shipped in 2024 replaced legacy steel vessels at multiproduct plants. For clinical-stage autologous therapies, disposables are non-negotiable due to patient-specific batch segregation. Collectively, these dynamics keep the single-use bioprocessing market on a steep adoption curve across both scales.

By End User: CDMOs Outpace Innovators

Biopharmaceutical innovators captured three-quarters of 2025 revenue, yet CDMOs exhibit the steeper trajectory. A BioProcess International survey reported 68% of CDMOs citing disposables as their principal multi-product enabler. Lonza deploys single-use formats in 85% of small-client suites, shortening cleaning turnarounds that would otherwise erode utilization. Government grants to universities and public labs also stipulate disposable platforms to maximize shared-facility uptime.

Academic demand is steady, anchored by flexibility needs in early trials. EMA guidance now lets Phase I and II batches run fully disposable without stainless comparability, unlocking early investment at smaller scales. As autologous therapies proliferate, end-user segmentation will continue to tilt toward organizations managing many products in parallel, a core advantage of the single-use bioprocessing market.

Geography Analysis

North America’s 35.23% revenue share in 2025 stemmed from BARDA’s pandemic-preparedness build-out, which specified modular disposable suites^{[3]Biomedical Advanced Research and Development Authority, “mRNA Vaccine Manufacturing Investment Program,” Phe.gov}. FDA’s advanced-manufacturing framework further validated the approach, prompting retrofit programs in legacy facilities. Canada directed CAD 2.2 billion (USD 1.6 billion) to bolster vaccine and biologic capacity, stipulating single-use platforms for multi-product flexibility. Mexican CDMOs expanded to capture nearshoring demand from U.S. biopharma, choosing disposables for rapid deployment.

Europe blends regulatory push and sustainability pull. The Single-Use Plastics Directive mandates producer take-back, nudging adoption of recyclable bag films. Germany earmarked EUR 800 million (USD 880 million) for continuous single-use hubs, while the UK MHRA updated validation guidance to cover hybrid workflows. France installed 18 new suites for biosimilar output, and Southern European facilities added roughly 10,000 L of disposable bioreactor capacity in 2025, primarily for fill-finish programs.

Asia-Pacific is set for the fastest growth at 15.42% CAGR. China’s 47 biosimilar approvals in 2025 sparked facility expansions that favor disposable trains over steel. India’s USD 500 million upgrade fund names single-use equipment an eligible expense. Japan’s PMDA guidance now permits disposables without comparability studies for biosimilars, accelerating local uptake. South Korean majors added 120,000 L of new capacity over 2024-2025, positioning the peninsula as a global CDMO hub. Emerging regions join the trend: the UAE committed USD 300 million to a disposable-based biosimilar JV, and South Africa’s Biovac installed a 2,000 L suite for vaccine surge capacity.

Regulatory Landscape

Regulatory expectations for single-use systems are tightening around polymer characterization, extractables and leachables (E&L), and sterile contamination control, while remaining broadly supportive of validated disposable substitutions for stainless equipment. In the United States, USP <665> became effective on May 1, 2026, formalizing baseline requirements for plastic components and systems used in manufacturing biopharmaceutical drug substances and products; this raises the bar for material traceability and testing packages across bags, tubing, connectors, and assemblies. In Europe, EU GMP Annex 1 continues to anchor sterile manufacturing through a contamination control strategy (CCS) and risk-based qualification that extends to single-use fluid paths, filters, and aseptic connections. For advanced therapies, the EMA guideline on quality, non-clinical, and clinical requirements for investigational ATMPs (effective July 1, 2025) reinforces robust manufacturing controls and documentation for closed, disposable workflows common in autologous cell therapies. Industry alignment efforts also advanced in April 2026 when BioPhorum and BPSA published an updated Single-Use User Requirements (SUUR) Toolkit aligned with ASTM E3051-25 and EU GMP Annex 1, helping standardize user-supplier communication for single-use qualification and change management.

Market Opportunities and Future Outlook

Opportunities are concentrating around capacity build-outs that standardize on single-use trains, plus enabling technologies that reduce changeover time and increase process control fidelity across multiproduct facilities. Multiple 2026 expansions highlight where demand is being operationalized: FUJIFILM Biotechnologies opened a USD 540 million expansion in Teesside, England featuring 2,000 L and 5,000 L single-use bioreactors (February 2026), WuXi Biologics completed its first GMP production campaign at its 9,000 L MFG17 drug substance facility in Shanghai using single-use bioreactors (June 2026), and Bora Biologics added a Rockville, Maryland site in July 2026, taking installed single-use bioreactor capacity to 20,000 L across two FDA-registered facilities. These projects expand the addressable pull-through for recurring consumables (bags, tubing, sterile connectors, filters) and for the supporting validation and E&L documentation demanded by customers operating under US and EU GMP frameworks.

White-space persists in downstream and in facility-wide interoperability where buyers want faster setup, fewer sterility breach points, and smoother digital integration. The push toward standardized sterile connection and fluid-management hardware is reinforced by new single-use disconnect formats introduced in 2026, while BioPhorum roadmapping work keeps attention on modularity, flexibility, and automation/analytics as enabling capabilities. Sustainability and circularity pressures, especially in Europe, also create room for take-back logistics and designs that support polymer recovery, with pilots such as the Sartorius-Veolia effort in Lyon providing a template for suppliers to differentiate beyond pure performance in tenders that increasingly include plastic-intensity and end-of-life requirements.